SU11652 | CAS#326914-10-7 | Tyrosine Kinase Receptor Antagonist

MedKoo Cat#: 532798 | Name: SU11652

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SU11652 is a potent cell-permeable pyrrole-indolinone compound that acts as an ATP-competitive tyrosine kinase receptor and angiogenic inhibitor that exhibits greater selectivity for PDGFR-β (PDGFRβ, IC50 = 3 nM), Flk-1 (VEGFR2, IC50 = 27 nM), FGFR1 (IC50= 170 nM), and Kit family members (IC50=~10-500 nM) over EGFR (IC50 >20 μM). SU11652 displays anti-proliferative and pro-apoptotic properties in tumor cells.

Chemical Structure

SU11652

CAS#326914-10-7

Theoretical Analysis

MedKoo Cat#: 532798

Name: SU11652

CAS#: 326914-10-7

Chemical Formula: C22H27ClN4O2

Exact Mass: 414.1823

Molecular Weight: 414.93

Elemental Analysis: C, 63.68; H, 6.56; Cl, 8.54; N, 13.50; O, 7.71

Price and Availability

Size	Price	Availability
5mg	USD 350.00	2 Weeks
10mg	USD 550.00	2 Weeks
25mg	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

SU11652; SU 11652; SU-11652.

IUPAC/Chemical Name

5-{[(3Z)-5-chloro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-N-[2-(diethylamino)ethyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide

InChi Key

XPLJEFSRINKZLC-ATVHPVEESA-N

InChi Code

InChI=1S/C22H27ClN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-

SMILES Code

O=C(C1=C(C)NC(/C=C2C(NC3=C\2C=C(Cl)C=C3)=O)=C1C)NCCN(CC)CC

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

SU11652 exhibits greater selectivity for PDGFRβ (IC50 = 3 nM), VEGFR2 (IC50 = 27 nM), FGFR1 (IC50 = 170 nM), and Kit family members (IC50 = ~ 10-500 nM) over EGFR (IC50 >20 µM). Reported to display anti-proliferative and pro-apoptotic properties in tumor cells.

In vitro activity:

SU11652 is a potent FLT3 inhibitor which selectively targets FLT3-ITD-positive cells. It should serve as a good candidate for development of therapeutic drugs to treat acute myeloid leukemia (AML). SU11652 strongly inhibited the activity of wild type, D835Y, and D835H mutant forms of FLT3 with IC50 values of 1.5, 16, and 32 nM, respectively. It effectively blocked the growth of FLT3-ITD -positive MV-4-11 cells, but exhibited much less effects on cells without FLT3 mutations. Reference: J Hematol Oncol. 2012 Dec 6;5:72. https://pubmed.ncbi.nlm.nih.gov/23216927/

In vivo activity:

To be determined

	Solvent	mg/mL	mM
Solubility
	DMSO	4.0	9.64

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 414.93 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Ellegaard AM, Groth-Pedersen L, Oorschot V, Klumperman J, Kirkegaard T, Nylandsted J, Jäättelä M. Sunitinib and SU11652 inhibit acid sphingomyelinase, destabilize lysosomes, and inhibit multidrug resistance. Mol Cancer Ther. 2013 Oct;12(10):2018-30. doi: 10.1158/1535-7163.MCT-13-0084. Epub 2013 Aug 6. PMID: 23920274. 2. Guo Y, Chen Y, Xu X, Fu X, Zhao ZJ. SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells. J Hematol Oncol. 2012 Dec 6;5:72. doi: 10.1186/1756-8722-5-72. PMID: 23216927; PMCID: PMC3524753.

In vitro protocol:

In vivo protocol:

To be determined

1: Vieira PS, de Arruda Campos Brasil Souza T, Honorato RV, Zanphorlin LM, Severiano KU, Rocco SA, Cavalcante de Oliveira AH, Cordeiro AT, Lopes de Oliveira PS, Oliveira de Giuseppe P, Murakami MT. Pyrrole-indolinone SU11652 targets the nucleoside diphosphate kinase from Leishmania parasites. Biochem Biophys Res Commun. 2017 May 9. pii: S0006-291X(17)30910-5. doi: 10.1016/j.bbrc.2017.05.048. [Epub ahead of print] PubMed PMID: 28499874. 2: Makihara N, Arimura K, Ago T, Tachibana M, Nishimura A, Nakamura K, Matsuo R, Wakisaka Y, Kuroda J, Sugimori H, Kamouchi M, Kitazono T. Involvement of platelet-derived growth factor receptor β in fibrosis through extracellular matrix protein production after ischemic stroke. Exp Neurol. 2015 Feb;264:127-34. doi: 10.1016/j.expneurol.2014.12.007. Epub 2014 Dec 13. PubMed PMID: 25510317. 3: Ellegaard AM, Groth-Pedersen L, Oorschot V, Klumperman J, Kirkegaard T, Nylandsted J, Jäättelä M. Sunitinib and SU11652 inhibit acid sphingomyelinase, destabilize lysosomes, and inhibit multidrug resistance. Mol Cancer Ther. 2013 Oct;12(10):2018-30. doi: 10.1158/1535-7163.MCT-13-0084. Epub 2013 Aug 6. PubMed PMID: 23920274. 4: Guo Y, Chen Y, Xu X, Fu X, Zhao ZJ. SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells. J Hematol Oncol. 2012 Dec 6;5:72. doi: 10.1186/1756-8722-5-72. PubMed PMID: 23216927; PubMed Central PMCID: PMC3524753. 5: Turpaev K, Drapier JC. Stimulatory effect of benzylidenemalononitrile tyrphostins on expression of NO-dependent genes in U-937 monocytic cells. Eur J Pharmacol. 2009 Mar 15;606(1-3):1-8. doi: 10.1016/j.ejphar.2009.01.015. Epub 2009 Jan 21. PubMed PMID: 19374863. 6: Heryanto B, Lipson KE, Rogers PA. Effect of angiogenesis inhibitors on oestrogen-mediated endometrial endothelial cell proliferation in the ovariectomized mouse. Reproduction. 2003 Mar;125(3):337-46. PubMed PMID: 12611597. 7: Liao AT, Chien MB, Shenoy N, Mendel DB, McMahon G, Cherrington JM, London CA. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood. 2002 Jul 15;100(2):585-93. Erratum in: Blood 2002 Oct 15;100(8):2696. PubMed PMID: 12091352.